首页> 外国专利> Kombinasjon av olmesartan medoksomil, eventuelt i form av et farmasøytisk akseptabelt salt, og amlodipinbesylat og hydroklortiazid

Kombinasjon av olmesartan medoksomil, eventuelt i form av et farmasøytisk akseptabelt salt, og amlodipinbesylat og hydroklortiazid

机译:奥美沙坦酯(可选地以药学上可接受的盐形式)与氨氯地平苯磺酸盐和氢氯噻嗪的组合

摘要

N-Phenylbenzyl imidazole derivs. of formula (I) and their pharmaceutically acceptable salts and esters are new. In (I), R1 = 1-6C alkyl or 3-6C alkenyl; R2 and R3 = H, 1-6C alkyl, 3-6C alkenyl, 3-10C cycloalkyl (opt. polycyclic), aryl(1-6C)alkyl, aryl or aryl fused to 3-10C cycloalkyl; R4 = H, 1-6C alkyl, 1-6C alkanoyl (opt. substd. by one or more halo or 1-6C alkoxy if other than formyl), 3-6C alkenoyl, arylcarbonyl, 1-6C alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl or tetrahydrofuryl (these 4 opt. substd. by one or more halo or 1-6C alkoxy), SiRaRbRc, 1-6C alkoxymethyl, 1-6C alkoxy(1-6C)alkoxymethyl, halo(1-6C)alkoxymethyl, 1-6C alkyl substd. by at least one aryl, or 1-6C alkanoyl-oxymethoxycarbonyl; Ra, Rb and Rc = 1-6C alkyl or aryl, but not all aryl; R5 = COOH or CONR8R9; R8 and R9 = H, 1-6C alkyl (opt. substd. by at least one (a)) or together are 2-6C alkylene opt. substd. by at least one COOH or alkoxycarbonyl; R6 = H, 1-6C alkyl or alkoxy, or halo; R7 = COOH or tetrazol-5-yl; (a) = aryl, 5-6 membered heterocyclic with 1-4 N, O and/or S, halo, OH, 1-6C alkoxy, COOH, 1-6C alkoxycarbonyl, NH2 or acylamino (acyl = 1-6C alkanoyl or arylcarbonyl); aryl = 6-14C aromatic carbocyclic gp. opt. substd. by at least one of NO2, CN, halo, 6-10C carbocyclic aryl (unsubstd.), 1-6C alkyl or alkoxy, COOH, 1-6C alkoxy-carbonyl, or 1-3C alkylenedioxy or alkylidenedioxy. 23 Cpds. e.g. pivaloyloxymethyl (or (5-methyl-2-oxo -1,3-dioxolen-4-yl)methyl) 4-(1-hydroxy-1-methylethyl) -2-(ethyl, propyl or butyl)-1-(4-(2-tetrazol -5-yl)phenyl)phenyl)methylimidazole -5-carboxylate.
机译:N-苯基苄基咪唑衍生物。式(I)的化合物及其药学上可接受的盐和酯是新的。在(I)中,R 1 = 1-6C烷基或3-6C烯基; R2和R3 = H,1-6C烷基,3-6C链烯基,3-10C环烷基(多环基),芳基(1-6C)烷基,芳基或与3-10C环烷基稠合的芳基; R4 = H,1-6C烷基,1-6C烷酰基(如果不是甲酰基则被一个或多个卤素或1-6C烷氧基取代),3-6C烯酰基,芳基羰基,1-6C烷氧基羰基,四氢吡喃基,四氢硫吡喃基,四氢噻吩基或四氢呋喃基(这4个选择基,由一个或多个卤素或1-6C烷氧基取代),SiRaRbRc,1-6C烷氧基甲基,1-6C烷氧基(1-6C)烷氧基甲基,卤素(1-6C)烷氧基甲基,1- 6C烷基取代。通过至少一个芳基或1-6C烷酰基-氧基甲氧基羰基; Ra,Rb和Rc = 1-6C烷基或芳基,但不是全部芳基; R5 = COOH或CONR8R9; R 8和R 9 = H,1-6C烷基(至少被一个(a)取代)或一起是2-6C亚烷基。取代通过至少一种COOH或烷氧羰基; R6 = H,1-6C烷基或烷氧基或卤素; R7 = COOH或四唑-5-基; (a)=芳基,具有1-4个N,O和/或S,卤素,OH,1-6C烷氧基,COOH,1-6C烷氧羰基,NH2或酰基氨基的5-6元杂环(酰基= 1-6C烷酰基或芳基羰基);芳基= 6-14C芳族碳环基gp。选择。取代通过NO 2,CN,卤素,6-10C碳环芳基(未取代),1-6C烷基或烷氧基,COOH,1-6C烷氧基-羰基或1-3C亚烷基二氧基或亚烷基二氧基中的至少一种。 23 Cpds。例如新戊酰氧基甲基(或(5-甲基-2-氧代-1,3-二氧戊环-4-基)甲基)4-(1-羟基-1-甲基乙基)-2-(乙基,丙基或丁基)-1-(4 -(2-四唑-5-基)苯基)苯基)咪唑基-5-羧酸酯。

著录项

  • 公开/公告号NO2011013I1

    专利类型

  • 公开/公告日2011-08-22

    原文格式PDF

  • 申请/专利权人 DAIICHI SANKYO CO LTD;

    申请/专利号NO20110000013C

  • 发明设计人

    申请日2011-08-10

  • 分类号A61K31/415;A61K;A61K31/41;A61K31/4164;A61K31/4174;A61K31/4178;A61K31/435;A61K31/44;A61K31/695;A61P9/12;A61P43;C07D;C07D233/60;C07D233/74;C07D233/90;C07D401/04;C07D401/14;C07D403/04;C07D403/06;C07D403/10;C07D403/14;C07D405/04;C07D405/12;C07D405/14;C07D407/12;C07D407/14;C07D409/12;C07D409/14;C07D413/14;C07D417/14;C07F7/10;C07F7/18;

  • 国家 NO

  • 入库时间 2022-08-21 18:05:12

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号